SLC5A2 and type 2 diabetes mellitus: Notwithstanding contradicting one prior study (16), our findings align with a meta-analysis that did not support the effect of SGLT-2 inhibitors targeting SLC5A2 on the risk of skin cancer in patients with T2D (18).